Metagenomic Sequencing - A Tool for Diagnosis of Central Nervous System Infection - Insights
PACE / State of FL This webinar will cover metagenomic sequencing for diagnosing central nervous system infection. Content will be shared regarding technical details, clinical applications, and results interpretation, drawing on both...
How Pathologists Support Successful Laboratory Outreach - Insights
A pathologist’s collaboration with the outreach team and referring physicians strengthens the program and provides the best service for patients.
Learn about our hereditary cancer test offerings, including single-gene assays that evaluate specific genes already identified in a parent.
Learn how reliable laboratory diagnosis of a platelet disorders can impact patients’ and their family members' clinical management and outcomes.
T-cell Lymphoma [Test in Focus] - Insights
Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.
4 statistics that showcase the broad impact of laboratory medicine - Insights
Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.
Gastrointestinal Pathogen Panel, PCR, Feces [Test in Focus] - Insights
The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.
Molecular Detection for Tuberculosis Drug Resistance [Test in Focus] - Insights
Nancy Wengenack, Ph.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be...
New Test Options for NTRK Gene Fusions - Insights
The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor....